List view / Grid view
1 April 2014 | By Daiichi Sankyo Company
First patient enrolled in largest planned phase 3 study evaluating a novel oral antico-agulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion...
1 April 2014 | By Lundbeck
H. Lundbeck A/S, together with a number of other companies, is now entering into a collaboration with the Lieber Institute, which has the world’s largest collection of human brains from patients with psychiatric disorders...
1 April 2014 | By Shire
Shire plc announced the acceptance of submission of a Marketing Authorisation Application by the European Medicines Agency for their once-daily, non-stimulant guanfacine extended release...
31 March 2014 | By Novartis
Novartis announced that the Data Monitoring Committee unanimously recommended early closure of the PARADIGM-HF study...
31 March 2014 | By Sanofi
Appointment is a first for a Top 10 Biopharmaceutical Company...
31 March 2014 | By GlaxoSmithKline
GSK announced a series of new investments in sub-Saharan Africa designed to address pressing health needs and contribute to long-term business growth...
28 March 2014 | By Novartis
Advisory Committee members voted against RLX030 for the treatment of acute heart failure (AHF)...
28 March 2014 | By Gilead Sciences
If approved, once-daily tablet would simplify therapy and eliminate need for Interferon and Ribavirin for Genotype 1 Hepatitis C patients in Europe...
28 March 2014 | By Cancer Research Technology (CRT)
A new cancer drug, based on further development of a discovery originally made by Cancer Research UK, has entered a clinical trial to target a wide range of cancers.
28 March 2014 | By Baxter International Inc.
Baxter International Inc. has announced plans to create two separate, independent global healthcare companies – one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products...
27 March 2014 | By GlaxoSmithKline
Novel scientific collaboration to use genomics and big data to drive drug discovery...
27 March 2014 | By Merck
Merck announced the appointment of Robert M. Davis as executive vice president and chief financial officer, effective April 23, 2014....
27 March 2014 | By Bristol-Myers Squibb
Blood pressure control key factor in stroke risk...
27 March 2014 | By WITec
TESCAN ORSAY HOLDING, a.s. and WITec GmbH jointly launch RISE Microscopy at Analytica 2014...
26 March 2014 | By The European Medicines Agency
Handling of all other evaluation procedures to remain unchanged until further announcement later this year...
